We previously demonstrated that more than 50% of recombinant antibodies (rAbs) generated from clonally expanded plasma cells in the cerebrospinal fluid (CSF) of an AQP4 seropositive NMO patient were directed against AQP4, and reproduced NMO pathology in the EAE model.